On 4/4/2017, Shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) closed at $0.6215 in last trading day. After noting the initial trading entry at $0.6489, it reached to a day’s high of $0.6489 and moved to a day’s low of $0.6100. The recent daily volume was 1.21 million as contrast to it’s an average volume of 454.23 thousand.
The last close of the AVEO Pharmaceuticals, Inc. stock reflects that it traded -21.1008% from its 50-day moving average of $0.7877. The stock traded below -12.0851% to its 200-day MA of $0.7069. Furthermore, it moved lower -45.9565% from its 52-week high of $1.1500 and +24.5491% up from $0.4990, which is 52-week low of the stock.
AVEO Pharmaceuticals, Inc.’s (AVEO) moved with shift of 8.77% in the past week. Over the last three months, the shares of the company have changed 3.33% and performed -28.74% over the last six months. The stock currently has Monthly Volatility of 9.32% and Weekly Volatility of 10.38%.
April 3, 2017 AVEO Oncology (AVEO) announced receipt of a $500,000 milestone payment from CANbridge Life Sciences Ltd., a biopharmaceutical company focused on developing western drug candidates in China and North Asia, related to a technology transfer milestone for AV-203, AVEO’s clinical-stage ErbB3 (HER3) inhibitory antibody candidate. AV-203 has demonstrated preclinical activity in a number of different tumor models including breast, head and neck, lung, ovarian and pancreatic cancers. CANbridge is planning clinical development of AV-203 in squamous cell esophageal cancer as its initial indication.
“Receipt of this milestone payment from CANbridge reflects continued progress by our partner to engineer the manufacturing process for AV-203 in an effort to develop an antibody manufacturing process suitable for commercialization,” said Michael Bailey, president and chief executive officer of AVEO. “We look forward to continued progress in this program, and with the balance of our partnered pipeline, including AV-380, a potentially disease modifying treatment for cachexia which is partnered with Novartis, and ficlatuzumab in development for squamous cell carcinoma of the head and neck and acute myeloid leukemia, which is partnered with Biodesix. With these programs advancing, we continue to focus on tivozanib, including continuing our execution of the TIVO-3 and TiNivo studies for our U.S. pivotal clinical strategy, and support of our licensee, EUSA Pharma, in its response to European regulators.”
United Parcel Service, Inc. (NYSE:UPS) finalized the last transaction at value of $106.63, with a daily change of +0.22% or +0.23 points. The company maintained volume of 2.14 million shares. In past trading day, the stock hit the maximum price of $106.70 and touched to minimum value of $105.70. It has a market cap of $ 92.77B.
As of last trade close, the stock is trading downside -11.47% from its one year high of $120.44 and moved +6.58% upward from $100.05, which is one year low of the stock.
The stock traded above +0.03% from its 50-day moving average of $106.60. Furthermore, the stock moved -3.74% to its 200-day MA of $ 110.77.
During the last month, United Parcel Service, Inc.’s (UPS) has changed 0.50% and performed -0.90% over the last 6 months. The mean rating score for this stock is at 2.70. This rating scale contains from 1 to 5 with 5 representing a Strong Sell, 1 signifying a Strong Buy and 3 demonstrating a Hold. The Volatility was noted at 1.14% in recent month and observed Weekly Volatility of 1.18%.